BioMarin Pharmaceutical Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
BioMarin Pharmaceutical Inc. develops drugs with a focus on rare disease treatments. Its portfolio consists of several commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
BioMarin Pharmaceutical Inc. is a net-positive Humankind Value company, with much of its positive value coming from Healthcare R&D ($19.9 B), Pharmaceuticals ($5.9 B), and Economic Value ($454.1 M). Positive value from Healthcare R&D and Pharmaceuticals includes the impact of an estimated 500,000 additional years lived by people worldwide. However, there is room for improvement with respect to Greenhouse Gases (-$131.5 M) and Air Pollution (-$16.7 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.